Clinical trial
Tolerability of MK0524A Versus Niacin Extended-Release (0524A-054)
NCT00378833 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00378833 |
|---|---|
| Title | Tolerability of MK0524A Versus Niacin Extended-Release (0524A-054) |
| Official title | A Worldwide, Multicenter, Double-Blind, Parallel Study to Evaluate the Tolerability of MK0524A Versus Niacin Extended-Release |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hypercholesterolemia, Hyperlipidemia |
| Intervention type | Drug |
| Interventions | niacin (+) laropiprant, niacin |
| Enrollment | 1,300 |
| Start date | Jul 1, 2006 |
| Primary completion | Mar 1, 2007 |
| Completion | Mar 1, 2007 |
| First posted | Sep 21, 2006 |
| Last update posted | Feb 16, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: